tirzepatide stops working for Women's Weight Loss: Why Clinics Prefer It How to wean off tirzepatide:

Responder endpoint definitions consisted of single, dual, and triple composite endpoints related to glycemic control, body weight, and hypoglycemia outcomes

R was discontinued and the patient was treated with Prednisone 60 mg/day

Daniel Drucker: GLP-1 medicines beyond diabetes and obesity with benefits for heart, kidney, liver, sleep apnea, substance use disorders, and even neurodegenerative diseases

Therapy helps with food noise, body image concerns, and support around weight gain fears.

Discover how GLP-1 receptor agonists affect lipid profiles, who may benefit from modest cholesterol improvements, and how these medications compare with statins and other lipid-lowering treatments in UK clinical practice.

But one of the most intriguing questions in longevity medicine is whether their benefits extend beyond weight loss to cellular aging itself